M&A Deal Summary |
|
|---|---|
| Date | 2015-09-30 |
| Target | Scioderm |
| Sector | Life Science |
| Buyer(s) | Amicus Therapeutics |
| Deal Type | Add-on Acquisition |
| Deal Value | 229M USD |
| Advisor(s) | J.P. Morgan Securities (Financial) Cooley (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2002 |
| Sector | Life Science |
| Revenue | 528M USD (2024) |
Amicus Therapeutics is a biotechnology company at the forefront of therapies for rare and orphan diseases. Amicus Therapeutics was founded in 2002 and is based in Princeton, New Jersey.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science M&A | 1 of 2 |
| Type: Add-on Acquisition M&A Deals | 1 of 2 |
| State: North Carolina M&A | 1 of 1 |
| Country: United States M&A | 1 of 2 |
| Year: 2015 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-09-20 |
Celenex
Columbus, Ohio, United States Celenex is a clinical stage gene therapy company. The lead programs in CLN6, CLN3, and CLN8 Batten disease are potential first-to-market curative therapies for these rare, devastating diseases. Celenex is based in Columbus, Ohio. |
Buy | $175M |